Compare BLND & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLND | INDV |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | 419 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.5M | 4.7B |
| IPO Year | 2021 | 2014 |
| Metric | BLND | INDV |
|---|---|---|
| Price | $1.07 | $36.02 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.13 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 05-07-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 58.33 | ★ 8100.00 |
| EPS | N/A | ★ 1.67 |
| Revenue | $123,585,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | ★ N/A | $21.50 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $1.08 | $22.56 |
| 52 Week High | $3.86 | $42.81 |
| Indicator | BLND | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 27.47 | 49.36 |
| Support Level | N/A | $35.49 |
| Resistance Level | $1.60 | $36.62 |
| Average True Range (ATR) | 0.07 | 0.88 |
| MACD | -0.03 | 0.31 |
| Stochastic Oscillator | 4.81 | 64.56 |
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).